
Salubris Biotherapeutics Reports Positive Interim Data from Phase 2 Heart Failure Trial of JK07
Salubris Biotherapeutics Announces Positive Interim Data from Phase 2 Trial of JK07 in Heart Failure Salubris Biotherapeutics a clinical-stage biotechnology company focused on developing innovative biologic therapies, has announced promising…












